Under the agreement, HHMI and Duke will use OpenDEL to perform selections against G-protein-coupled receptor targets. OpenDEL is an affordable self-service drug discovery DEL platform for startups, biotechs, and academic researchers.

The effort will be headed by 2012 Nobel Prize in Chemistry awardee Dr. Robert Lefkowitz, a professor of medicine and biochemistry and chemistry at Duke and a principal investigator at HHMI, and Dr. Howard Rockman, a professor of cardiology and medicine and cell biology at Duke.